Cancer drugs in the united states: Justum pretium-the just price

Journal of Clinical Oncology

Volumn 31, Issue 28, 2013, Pages 3600-3604

  Kantarjian, Hagop M ^a   Fojo , Tito ^b   Mathisen, Michael ^a   Zwelling, Leonard A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; DASATINIB; EVEROLIMUS; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; DRUG COST; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MEDICARE; NEOPLASM; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; SALVAGE THERAPY; UNITED STATES; ECONOMICS; LEGAL ASPECT; LEGISLATION AND JURISPRUDENCE; NEOPLASMS; TRENDS;

ANTINEOPLASTIC AGENTS; DRUG COSTS; HUMANS; NEOPLASMS; UNITED STATES;

EID: 84886719809     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.1845     Document Type: Article

References (49)

1. National health expenditure projections 2011-2020. http://www.cms.gov/ Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ NationalHealthExpendData/Downloads/Proj2011PDF.pdf
2. Board of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds: 2012 Annual Report. https://www.cms.gov/ReportsTrustFunds/downloads/tr2012.pdf
3. Himmelstein D, Woolhandler S: Cost control in a parallel universe: Medicare spending in the United States and Canada. Arch Intern Med 172: 1764-1766, 2012
4. Fojo T, Grady C: How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101:1044-1048, 2009
5. Smith TJ, Hillner BE: Bending the cost curve in cancer care. N Engl J Med 364:2060-2065, 2011
6. Elkin EB, Bach PB: Cancer's next frontier, addressing high and increasing costs. JAMA 303: 1086-1087, 2010
7. Hillner BE, Smith TJ: Efficacy does not necessarily translate to cost effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 27:2111-2113, 2009
8. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
9. Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
10. Bach P, Salz L, Wittes R: In cancer care, cost matters. New York Times, October 15, 2012:A25
11. Truven Health Analytics: Red Book online. http://www.redbook.com/redbook/ index.html
12. Goozer M: The $800 Million Pill: The Truth Behind the Cost of New Drugs. Berkeley, CA, University of California Press, 2004
13. Angell M: The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York, NY, Random House Trade Paperbacks, 2004
14. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: New estimates of drug development costs. J Health Econ 22:151-185, 2003
15. Light DW, Warburton R: Demythologizing the high costs of pharmaceutical research. BioSocieties 1745-8552:1-17, 2011
16. Huff EA: Big pharma lies about R&D costs to justify illicit profits. http://www.naturalnews.com/031657-Big-Pharma-drug-development-costs.html
17. Light DW: Advanced Market Commitments: Current Realities and Alternate Approaches. Amsterdam, the Netherlands, HAI Europe/Medico International Publication, 2009, pp 14-17
18. Kantarjian H, O'Brien S: The chronic leukemias, in Goldman L, Schafer A, Arend W, (eds): Cecil Medicine (ed 24). Philadelphia, PA, Elsevier Saunders, 2012, pp 1209-1218
19. Healthwatcher: US patient petition calling for reduction of Gleevec price. http://healthwatched.org/2012/05/09/us-patient-petition-calling-for- reduction-of-gleevecprice/
20. Huang X, Cortes J, Kantarjian H: Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118:3123-3127, 2012
21. Kantarjian HM, Hochhaus A, Saglio G, et al: Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncology 12:841-851, 2011
22. Kantarjian HM, Shah NP, Cortes JE, et al: Dasatinib or imatinib in newly diagnosed chronicphase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119:1123-1129, 2012
23. Escudier B, Szczylik C, Hutson TE, et al: Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 1280-1289, 2009
24. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590, 2009
25. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind phase III trial. Lancet 370:2103-2111, 2007
26. Rini B, Halabi S, Rosenberg JE, et al: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428, 2008
27. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007
28. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
29. Shah B, Ghimire K, Lewiston ID: Survival trends among patients with advanced renal cell carcinoma (RCC) in the United States. J Clin Oncol 31, 2013 (suppl; abstr 422)
30. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
31. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011
32. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
33. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
34. Stewart DJ, Whitney SN, Kurzrock R: Equipoise lost: Ethics, costs, and the regulation of cancer clinical research. J Clin Oncol 28:2925-2935, 2010
35. Steensma DP: The ordinary miracle of cancer clinical trials. J Clin Oncol 27:1737-1739, 2009
36. Dilts DM, Sandler AB, Cheng SK, et al: Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. J Clin Oncol 27:1761-1766, 2009
37. Dilts DM, Sandler A, Cheng S, et al: Development of clinical trials in a cooperative group setting: The Eastern Cooperative Oncology Group. Clin Cancer Res 14:3427-3433, 2008
38. Dilts DM, Sandler AB: Invisible barriers to clinical trials: The impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 24:4545-4552, 2006
39. Stewart DJ, Kurzrock R: Cancer: The road to Amiens. J Clin Oncol 27:328-333, 2009
40. Naing A, Veasey-Rodrigues H, Hong DS, et al: Electrocardiograms (ECGs) in phase I anticancer drug development: The MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 23:2960-2963, 2012
41. Whoriskey P: As drug industry's influence over research grows, so does the potential for bias. Washington Post, November 24, 2012. http://articles. washing tonpost.com/2012-11-24/business/35511825-1-drugcompanies-avandia-steven- e-nissen
42. Baker D: The savings from an efficient Medicare prescription drug plan. http://www.cepr.net/documents/efficient-medicare-2006-01.pdf
43. Wyatt E: Justices to take up generic drug case. New York Times, December 8, 2012:B1
44. Lee CP, Chertow GM, Zenios SA: An empiric estimate of the value of life: Updating the renal dialysis cost-effectiveness standard. Value Health 12:80-87, 2009
45. Rascati KL: The $64,000 question: What is a quality-adjusted life year worth? Clin Ther 28:1042-1043, 2006
46. Zarate V: DALYs and QALYs in developing countries. Health Aff (Millwood) 26:1197-1198, 2007
47. Cohen H: Drug Topics Red Book (ed 112). Montvale, NJ, Thomson Healthcare/Thomson PDR, 2008
48. Nass SJ, Balogh E, Mendelsohn J: A National Cancer Clinical Trials Network: Recommendations from the Institute of Medicine. Amer J Ther 18:382-391, 2011
49. Himmelstein DU, Thorne D, Warren E, et al: Medical bankruptcy in the United States, 2007: Results of a national study. Am J Med 122:741-746, 2009